Intact Therapeutics is developing INT-201, a new product for the treatment of upper gastrointestinal bleeding (UGIB). Intact Therapeutics’ disruptive technology is based on a proprietary, poloxamer-based thermogel formulation which is able to block the flow of blood in the upper gastrointestinal tract without the need for endoscopic treatment. INT-201 has an innovative formulation designed to provide superior mucoadhesion for the GI tract.